*Sponsored content
Jürgen Polifka, Director of Global Market Access at Advanz Pharma, provides a Special Report on the company's approach to securing rapid access for essential medicines.
The generics industry has become a key player in enabling healthcare systems to manage tight budget constraints; promoting the widest possible access to affordable medicines with quality, safety, and efficacy. It’s therefore essential for pharmaceutical companies to have dynamic market access strategies in place, that ensure safe and timely access to the medicines patients depend on.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze